Does Insurance Cover GLP-1 Weight Loss Medications in Texas?

There is no universal answer to whether insurance covers GLP-1 medications for weight loss in Texas. Coverage depends entirely on your individual plan. Some commercial insurance plans cover Wegovy (semaglutide) and Zepbound (tirzepatide) with prior authorization. Many do not. Texas Medicaid does not currently cover weight-loss medications. Medicare Part D plans were prohibited from covering weight-loss drugs under federal law until the TRCARE Act passed in late 2024 — coverage implementation has been rolling out gradually.

The most reliable way to find out what your plan covers is to call the member services number on the back of your insurance card and ask specifically: 'Does my plan cover Wegovy or Zepbound? Is prior authorization required? What BMI and comorbidity criteria does my plan require?'

Don't assume a plan covers or doesn't cover these medications based on what you've heard from someone else. Plan benefits vary by employer, by plan tier, and by year.

If your plan covers GLP-1 medications for weight loss, it almost certainly requires prior authorization — a formal approval process before the medication is dispensed. Prior authorization for weight-loss medications typically requires documented BMI criteria (usually BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or high cholesterol), evidence that prior weight-loss interventions have been attempted, and a prescription from a licensed provider.

The prior authorization request is submitted by your prescribing provider, not by you. This means working with a physician-supervised program that is equipped to handle the prior auth process is meaningfully better than a telehealth service that hands you a prescription and leaves insurance navigation to you.

Prior auth approvals are not guaranteed. Insurance companies deny approximately 20 to 30 percent of GLP-1 weight-loss authorizations on the first submission, often for documentation reasons rather than medical necessity. Understanding how to appeal is important.

A denial is not necessarily final. If your prior authorization is denied, you have the right to appeal. First-level appeals (internal appeals to the insurance company) reverse approximately 40 to 50 percent of denials when submitted with adequate medical documentation. The appeal should include a letter of medical necessity from your provider, documentation of comorbidities, and evidence of prior treatment attempts.

If the internal appeal is denied, you can request an external review by an independent organization — this is a legal right in Texas under state insurance law. External reviews result in overturned decisions in a meaningful percentage of cases.

Manufacturer assistance programs can be a bridge during the appeal process. Novo Nordisk and Eli Lilly both have patient assistance programs for Wegovy and Zepbound, respectively, that may provide medication at no or reduced cost while coverage is being resolved. Eligibility criteria apply.

Texas does not require private insurers to cover obesity medications, which means coverage is entirely voluntary at the plan level. Large employer self-insured plans in Texas have been adding GLP-1 coverage faster than fully-insured small-group plans as the evidence base for these medications strengthens.

State employee health plans in Texas (TexSelect/TexFlex plans through the Employee Retirement System of Texas) have inconsistently covered weight-loss medications. If you're a Texas state employee, check your current plan benefit documents specifically — coverage status has changed in recent plan years.

ACA marketplace plans in Texas vary significantly. Some bronze and silver tier marketplace plans cover GLP-1 medications with significant cost-sharing; others exclude them entirely. When selecting a marketplace plan during open enrollment, specifically checking formulary coverage for Wegovy and Zepbound can meaningfully affect your annual out-of-pocket costs if you're pursuing a GLP-1 program.